通过CRISPR-Cas9调节的TSC2病原变异的纠正,来自2型结核性硬化综合体患者的iPSC
Gongbo Guo1, Morgan Moser1, Lincoln Chifamba1
1The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
The CRISPR journal
|December 10, 2024
概括
结核性硬化综合体 (TSC) 是一种遗传性疾病. 研究人员使用CRISPR基因编辑来纠正患者细胞中的TSC2基因突变,为疾病研究和治疗开发创造了有价值的工具.
科学领域:
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
- 干细胞研究 干细胞研究
背景情况:
- 结核性硬化综合体 (TSC) 是一种由TSC1或TSC2基因突变引起的自体主导性疾病.
- 神经系统并发症是TSC患者死亡和发病的主要原因.
- 致病性TSC2变异比TSC1变异更为常见,TSC经常偶尔发生.
研究的目的:
- 在患者衍生的诱导多能干细胞 (iPSCs) 中使用CRISPR-Cas9纠正TSC2基因中的致病变异.
- 产生异构细胞系用于TSC疾病建模和治疗开发.
主要方法:
- 利用CRISPR-Cas9介导的同质性定向修复来纠正患者iPSC中的两个不同的TSC2致病变体.
- 产生了两个同源细胞系:一个纠正拼接受体变体 (c.2743-1G>A),另一个纠正误解变体 (c.5228G>A,p.R1743Q).
主要成果:
- 在使用CRISPR-Cas9技术的患者iPSC中成功纠正引起疾病的TSC2变异.
- 生成同位素TSC2患者的iPSC线,对于比较研究至关重要.
结论:
- 开发出来的同源细胞系是研究TSC病变的宝贵工具.
- 这些细胞系将有助于开发和测试用于结核性硬化综合体的新疗法.
相关概念视频
01:22iPS Cell Differentiation
2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
01:59CRISPR
49.4K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
49.4K